Diagnosis kit for skin test and method for carrying out the same

Claims

1. A skin test diagnosis kit for detecting an immune reaction against the oncoprotein E6 and/or E7 of a human papilloma virus type, said diagnosis kit containing an effective amount of the oncoprotein E6 and/or E7 and/or at least an immunologically effective portion of E6 and/or E7 of a human papilloma virus type.

2. The diagnosis kit of claim 1, characterized in that the contained portion of the oncoprotein is derived from HPV16.

3. The diagnosis kit of claim 1 ~~or 2,~~ characterized in that the immunologically effective portion of the human papilloma virus type is at least one synthetically produced peptide.

4. The diagnosis kit of claim 1 ~~any of the preceding claims~~, characterized in that the contained oncoprotein E7 or the immunologically effective portion thereof is or are from HPV16.

5. The diagnosis kit of claim 1 ~~any of the preceding claims~~, characterized in that the contained oncoprotein or the immunologically effective portion thereof is dissolved in a solvent.

6. The diagnosis kit of claim 5, characterized in that the solvent is 70% glycerin.

7. The diagnosis kit of ~~any of the preceding claims,~~ claim 1 characterized in that the amount of oncoprotein or the immunologically effective portion is 0.01 to 10 µg per charge to be applied.

8. The diagnosis kit of ~~any of the preceding claims~~, claim 1 characterized in that said diagnosis kit further comprises an applicator, by means of which said effective amount of the oncoprotein or the immunologically effective portion thereof can be injected intracutaneously.

9. The diagnosis kit of claim 8, characterized in that said applicator is a syringe.

10. The diagnosis kit of claim 8, characterized in that said applicator is a test stamp as used, for example, for the TINE test or the multitest "Sero".

11. A process for carrying out a skin test for detecting an immunological response with respect to the oncoproteins E6 and/or E7 of an HPV type, comprising the following steps:

a) providing a diagnosis kit of ~~any of claims 1 to 9~~; claim 1

b) intracutaneous application of an effective amount of at least one oncoprotein E6 and E7 or effective portions thereof into a test person;

c) after a sufficient incubation time, visual inspection of the skin regions of the application to detect an immunological response.

12. The process of claim 11, characterized in that the visual inspection of the skin region takes place one week after application of the oncoprotein.

Add C16)

gnp (15)